
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+4
Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgens xLinkAbTM functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs. Lyvgens most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409, a mAb agonist for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGF1/2/3, and anti-PD-1 blocking antibody LVGN3616. Lyvgen has initiated Phase I clinical trial of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA. Lyvgen plans to start Phase I testing of LVGN6051 in China, LVGN7409 and LVGN1673 globally. Lyvgen...
Antibody,io,immunotherapy,drug discovery,clinical trial,cmc,cancer,immunology,and ind
Lyvgen biopharma operates in the Biotechnology industry.
Lyvgen biopharma's revenue is 11m - 100m
Lyvgen biopharma has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.